Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit

a non-digestible oligosaccharide, breast milk technology, applied in the direction of antibody medical ingredients, drug compositions, immunological disorders, etc., can solve the problems of not being technically and economically feasible to prepare infant nutrition, complicated large-scale synthesis, etc., and achieve the effect of complicated large-scale synthesis

Inactive Publication Date: 2016-06-09
NV NUTRICIA
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0013]Recently, new techniques have become available to chemically synthesise specific types of NDO identical to specific human NDO, thereby offering the opportunity to test the immunomodulatory capacity of specific human NDO in in vitro and in vivo assays.
[0014]The inventors unexpectedly have found that fucosyllactose (FL), an oligosaccharide abundantly present in human breast milk and with a relatively simple structure, specifically increases the number and thereby the activity of Natural Killer (NK) cells. NK cells play an important role in the natural defence against viral infections and tumour cells. The finding which specific oligosaccharide is responsible for increasing NK cell activity now enables the design of nutritional compositions comprising FL, more particularly 2′-FL, for the use of increasing NK cells and / or NK cell activity.

Problems solved by technology

Because of their complex and polymorphic structure, large-scale synthesis is complicated.
It is therefore not yet technically and economically feasible to prepare infant nutrition with an NDO composition identical to human milk.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0060]Materials and Methods

[0061]6-8 Weeks old female C57BL / 6 mice (Charles River) received semi-purified AIN-93G-based diets (Research Diet Service, Wijk bij Duurstede, the Netherlands), comprising

[0062]1) 2 wt % beta-galacto-oligosaccharide (GOS; source Vivinal GOS, Borculo Domo), fructo-oligosaccharide (FOS; source RaftilineHP, Orafti) and galacturonic acid oligosaccharide (Source AOS) in a 9:1:1.1 ratio. AOS are produced from pectin (Südzucker AG, Mannheim, Germany), with a DP of 1-20. It consists of approximately 75% galacturonic acid oligomers, based on total weight;

[0063]2) 1 wt % lactoneotetraose (LNnT),

[0064]3) 1 wt % 3′-sialyl lactose (3′-SL), or

[0065]4) 1 wt % 2′-fucosyllactose (2′-FL).

[0066]All groups were compared to the unsupplemented control diet. Dietary supplementation started 14 days before the first vaccination and lasted until the end of the experiment, 31 days after the first vaccination.

[0067]Vaccination experiments were performed using Influvac (Solvay Pharmac...

example 2

[0076]Infant formula for stimulating NK cell activity comprising per 100 ml (13.9 dry weight):

[0077]1.4 g protein (whey and casein)

[0078]7.3 g digestible carbohydrates (including lactose)

[0079]3.6 g fat (vegetable fat, fish oil)

[0080]0.8 g non-digestible oligosaccharides of which 80 mg 2′-fucosyllactose and 640 mg beta-galacto-oligosaccharides, and 80 mg fructo-oligosaccharides

[0081]Further are included: choline, myo-inositol, taurine, minerals, trace elements, and vitamins as known in the art.

example 3

[0082]A preferred composition that can be used for the stimulation of natural killer cell activity in HIV patients may comprise per 100 g dry weight.

Dietary fibre 5-50 gFructo-oligosaccharide 5% of total dietary fibreGalacto-oligosaccharide40% of total dietary fibrePectin hydrolysate50% of total dietary fibre2′-FL 5% of total dietary fibreN-acetyl cysteine0.5-5 gCarbohydrate (not dietary fibre) 2-20 gFat 4-20 g

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
weight ratioaaaaaaaaaa
weight ratioaaaaaaaaaa
wt. %aaaaaaaaaa
Login to View More

Abstract

The invention concerns nutritional compositions with fucosyllactose for use in stimulation of NK cells. The composition is suitable for infants.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a Continuation of U.S. patent application Ser. No. 13 / 383,822, filed Mar. 28, 2012, which is the U.S. National Stage Application of PCT / NL2010 / 50447, filed Jul. 12, 2010, which claims the benefit of U.S. Provisional Patent Application No. 61 / 256,453, filed Oct. 30, 2009, and European Patent Application No. 09165485.5, filed Jul. 15, 2009, all of which are incorporated by reference in their entirety.FIELD OF THE INVENTION[0002]The present invention relates to infant nutrition with non-digestible oligosaccharides, in particular to the use thereof for stimulating the immune system.BACKGROUND OF THE INVENTION[0003]Human milk fed infants have a lower incidence of infections, including viral infections, than formula fed infants. Many components in human milk, including immunoglobulins (such as IgA), interleukin (IL)-1, IL-6, IL-8, IL-10, interferon-γ (IFN-γ), immunocompetent cells, transforming growth factor-β (TGF-β), lacto...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/39A61K31/7032A23L33/00
CPCA61K39/39A61K31/7032A23L1/30A23V2002/00A61K2039/572A61K2039/55A23L1/296A61K31/702A23L29/30A23L33/40A23L33/10A61P31/12A23L33/125A23L5/00A61K2300/00A23V2250/28A23V2200/308A23V2200/324A61P37/04
Inventor STAHL, BERNDNAUTA, ALMA JILDOUGARSSEN, JOHANSAMAIN, ERICDROUILLARD, SOPHIE
Owner NV NUTRICIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com